# SUPPLEMENTAL SPECIALTY PA

# **VEMLIDY** (tenofovir alafenamide)

### **POLICY**

### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

# **FDA-Approved Indications**

Treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

All other indications are considered experimental/investigational and not medically necessary.

# II. CRITERIA FOR INITIAL APPROVAL

# Chronic hepatitis B virus infection

Authorization of 6 months may be granted for treatment of chronic hepatitis B virus (HBV) when all of the following criteria are met:

- A. Member is HIV-1 negative
- B. Member has compensated liver disease as evidenced by:
  - 1. No evidence of ascites, hepatic encephalopathy, or variceal bleeding
  - 2. INR < 1.5x ULN
  - 3. Total bilirubin < 2.5x ULN
  - 4. Albumin > 3.0 g/dL

# **III. CONTINUATION OF THERAPY**

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for chronic HBV who achieve or maintain positive clinical response (e.g., decreased HBV DNA level, ALT normalization, HBsAg and/or HBeAg loss and seroconversion) and are HIV-1 negative.

### **IV. REFERENCES**

1. Vemlidy [package insert]. Foster City, CA: Gilead Sciences, Inc.; September 2021.

Vemlidy 2901-A Supplemental Specialty PA P2022

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2022 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of